IBERE PHARMACEUTICALS

Ibere Pharmaceuticals (Nasdaq: IBER) is a blank-check company that completed its initial public offering in 2021 with a stated focus on acquisition targets in the pharmaceutical and biotechnology sector. The company filed an amended quarterly report on Form 10-Q/A with the Securities and Exchange Commission on August 16, 2021, under accession number 0001104659-21-106486, reflecting revisions to previously submitted financial disclosures. IBER was formed to identify and execute a business combination with a life sciences target, placing it within the healthcare SPAC cohort that saw significant activity during the 2020–2021 market cycle. For complete filing history, deal timelines, and status tracking on IBER and hundreds of other SPACs, sign up for full data access at SpacDesk.